

1 **Overweight and Obesity as Predictors of Post-acute Sequelae of SARS-Cov-2 Infection:** 2 **Findings from the RECOVER Initiative**

3 Ting Zhou, MD, PhD^{1,2}, Bingyu Zhang, MS^{1,3}, Dazheng Zhang, MS^{1,2}, Qiong Wu, PhD^{1,2}, Michael J.
4 Becich, MD, PhD⁴, Saul Blecker, MD, MHS⁵, Jiajie Chen, PhD^{1,2}, Nymisha Chilukuri, MD⁶, Elizabeth A.
5 Chrischilles, PhD⁷, Haitao Chu, MD, PhD^{8,9}, Leonor Corsino, MD¹⁰, Carol R. Geary, PhD¹¹, Mady Hornig,
6 MA, MD¹², Susan Kim, MD, MMSc¹³, David M. Liebovitz, MD¹⁴, Vitaly Lorman, PhD¹⁵, Yiwen Lu, BS^{1,3},
7 Chongliang Luo, PhD¹⁶, Hiroki Morizono, PhD¹⁷, Abu SM. Mosa, PhD, MS, FAMIA¹⁸, Nathan M. Pajor,
8 MD, MS^{19,20}, Suchitra Rao, MBBS, MSCS²¹, Hanieh Razzaghi, PhD¹⁵, Srinivasan Suresh, MD, MBA^{22,23},
9 Yacob G. Tedla, PhD²⁴, Leah Vance Utset, MD²⁵, Youfa Wang, MD, PhD²⁶, David A. Williams, PhD²⁷,
10 Margot Gage Witvliet, PhD²⁸, Caren Mangarelli, MD, MS²⁹, Ravi Jhaveri, MD³⁰, Christopher B. Forrest,
11 MD, PhD^{15*}, and Yong Chen, PhD^{1,2,3,31,32, 33*}

12 1 The Center for Health Analytics and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA

13 2 Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine,
14 Philadelphia, PA, USA

15 3 The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of
16 Pennsylvania, Philadelphia, PA, USA

17 4 Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

18 5 Department of Population Health, New York University Grossman School of Medicine, NY, USA

19 6 Departments Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

20 7 Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, USA

21 8 Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, USA

22 9 Statistical Research and Innovation, Global Biometrics and Data Management, Pfizer Inc, New York, NY

23 10 Department of Medicine, Duke University School of Medicine, Durham, NC, USA

24 11 Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE, USA

25 12 Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA

26 13 Department of Pediatrics, Division of Rheumatology, UCSF Benioff Children's Hospital, San Francisco, CA, USA

27 14 Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

28 15 Applied Clinical Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

29 16. Division of Public Health Sciences, Washington University School of Medicine in St Louis, St Louis, MO, USA

30 17. Center for Genetic Medicine Research, Children's Research Institute, Children's National Hospital, Washington, DC, USA

31 18 Department of Health Management and Informatics, University of Missouri School of Medicine, Columbia, MO, USA

32 19. Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

- 33 20 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
34 21 Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
35 22 Divisions of Health Informatics & Emergency Medicine, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA,
36 USA
37 23 UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
38 24 Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
39 25. Division of Primary Care Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
40 26 Global Health Institute, Xi'an Jiaotong University, Xi'an, China
41 27 Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA
42 28 Department of Sociology, Social Work and Criminal Justice, Lamar University, Beaumont, TX, USA
43 29. Division of Advanced General Pediatrics and Primary Care, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago,
44 IL, USA
45 30. Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
46 31. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA
47 32. Penn Medicine Center for Evidence based Practice (CEP), University of Pennsylvania, Philadelphia, PA, USA
48 33. Penn Institute for Biomedical Informatics (IBI), University of Pennsylvania, Philadelphia, PA, USA

49 **Corresponding author:**

50 Yong Chen, PhD, ychen123@pennmedicine.upenn.edu
51 Christopher B. Forrest, MD, PhD, forrestc@chop.edu

52 **Authorship Statement:** Authorship has been determined according to ICMJE recommendations.
53 **Word count:** 2998

54 **Key Points**

55 **Question** Do children, adolescents, and young adults with overweight and obesity have increased risk of
56 developing post-acute sequelae of SARS-Cov-2 infection (PASC)?

57 **Findings** Overweight, obesity, and severe obesity were associated with significantly increased risk of
58 pediatric PASC. Compared with pediatrics with body mass index in the healthy range, those who were
59 overweight, obesity, or severely obesity had an increased incidence of 4.7%, 25.4%, and 42.1% of PASC,
60 respectively.

61 **Meaning** Overweight and obesity are important risk factors for pediatric PASC. The biological
62 mechanisms for this association should be investigated in the future research.

63 **Abstract**

64 **IMPORTANCE** Obesity increases the severe COVID-19 risk. Whether obesity is associated with an
65 increased risk of post-acute sequelae of SARS-Cov-2 infection (PASC) among pediatrics, independent of
66 its impacts on acute infection severity, is unclear.

67 **OBJECTIVE** To quantify the association between body mass index (BMI) status before SARS-CoV-2
68 infection and pediatric PASC risk, controlling for acute infection severity.

69 **DESIGN** Retrospective cohort study occurred from March 2020 to May 2023, with a minimal follow-up
70 of 179 days.

71 **SETTING** Twenty-six US children's hospitals.

72 **PARTICIPANTS** Individuals aged 5-20 years with SARS-CoV-2 infection.

73 **EXPOSURES** Elevated BMI status assessed before infection.

74 **MAIN OUTCOMES AND MEASURES** To identify PASC, we first used the ICD-10-CM code specific
75 for post-COVID-19 conditions, and a second approach used clusters of symptoms and conditions that
76 constitute the PASC phenotype. BMI was assessed within 18 months before infection; the measure closest
77 to the index date was selected. Relative risk (RR) for BMI-PASC association was quantified by Poisson
78 regression models, adjusting for sociodemographic, acute COVID severity, and other clinical factors.

79 **RESULTS** Among the 172136 participants included, the median age of BMI assessment and cohort entry
80 were 12.8 and 13.2 years, 1402 (0.8%) were identified as having PASC with the ICD-10-CM code, and
81 74317 (43.2%) had ≥ 1 incident occurrence of PASC symptoms and conditions. Compared with
82 participants with a healthy weight, those who had overweight, obesity, and severe obesity had 4.7% (RR,
83 1.047; 95% CI, 0.868-1.263), 25.4% (RR, 1.254; 95% CI, 1.064-1.478) and 42.1% (RR, 1.421; 95% CI,
84 1.253-1.611) higher risk of PASC when identified using the diagnosis code, respectively. The risk for any

85 occurrences of PASC symptoms and conditions also increased in overweight (RR, 1.030; 95% CI, 0.982-
86 1.080), obesity (RR, 1.108; 95% CI, 1.064-1.154), and severe obesity (RR, 1.174; 95% CI, 1.138-1.213),
87 and that for total incident occurrences increased, too, in overweight (RR, 1.053; 95% CI, 1.000-1.109),
88 obesity (RR, 1.137; 95% CI, 1.088-1.188), and severe obesity (RR, 1.182; 95% CI, 1.142-1.223).

89 **CONCLUSIONS AND RELEVANCE** Elevated BMI was associated with a significantly increased
90 PASC risk in a dose-dependent manner. The biological mechanisms for this association should be
91 investigated in future research.

92 Post-acute sequelae of SARS-CoV-2 infection (PASC) encompasses a broad and heterogeneous array of
93 persistent, relapsing, or newly emerging symptoms persisting beyond at least 4 weeks after the acute
94 phase of COVID-19.¹⁻⁴ This condition exhibits multifaceted involvement across various organ systems.⁵⁻⁸
95 The prevalence of pediatric PASC with SARS-CoV-2 infection varies across studies with reported rates
96 ranging from 1.6% to 70%.⁹⁻¹² PASC continues to pose a significant threat to children and there is an
97 urgent imperative for a deeper understanding of the pediatric PASC causes, which is a research priority
98 underscored in the updated National Institute for Health and Care Excellence guideline.¹³ This imperative
99 persists, emphasizing the ongoing need to unravel the complexities surrounding pediatric PASC even
100 after the pandemic.

101 Obesity is now one of the most common chronic diseases in the US, impacting over 40% of adults and
102 about 20% of children.^{14,15} The association of obesity with severe adverse outcomes was seen again with
103 the onset of the COVID-19 pandemic.¹⁶ The association between obesity as a risk factor and PASC has
104 been widely discussed, with a predominant focus on adults.^{17,18} Some studies have reported that
105 overweight or obesity is associated with an elevated risk of PASC^{18,19} across different timelines,
106 irrespective of whether the definition of PASC extends to 12 weeks¹⁸ or 4 months.¹⁹ However, the
107 nuances of this relationship become apparent when considering the specific timeline for defining PASC.
108 For example, Sudre et al. observed that increasing body mass index (BMI) and obesity were linked to
109 higher odds of PASC lasting for more than 4 weeks, but this association did not extend to PASC lasting
110 for more than 12 weeks.²⁰

111 The major concern is the limited attention given to the pediatric population, as the previous investigations
112 predominantly concentrated on adults. There is hardly any discussion regarding the pediatric BMI-PASC
113 association, which underscores a crucial research gap. To address these limitations and enhance our
114 understanding, large-scale studies using routinely available healthcare data among pediatric population
115 are needed. Our study conducted an extensive analysis utilizing EHR data sourced from 26 US children's
116 hospitals. The primary objective was to explore the relationship between BMI status before SARS-CoV-2

117 infection and a range of PASC definitions among both hospitalized and non-hospitalized pediatric
118 populations with COVID-19 infection, controlling for acute infection severity. We also assessed
119 associations between BMI status and the number of PASC symptoms and conditions accounting for
120 sociodemographic and clinical risk factors. Importantly, the insights obtained will play an influential role
121 in informing preventive and clinical management strategies, assisting healthcare providers in identifying
122 at-risk pediatric patients to develop PASC.

123 **Methods**

124 **Data Sources**

125 This study is part of the National Institutes of Health Researching COVID-19 to Enhance Recovery
126 (<https://recovercovid.org/>), which aims to understand, treat, and prevent PASC. Twenty-six institutions
127 contributed to the data (see eTable 1 in the Supplement for details).

128 We conducted a retrospective cohort study from March 2020 to May 2023 by including documented
129 SARS-CoV-2 infected patients under the age of 21 who had at least one visit within the baseline period of
130 18 months to 7 days prior to the index date and had at least one visit within the follow-up period of 28
131 days to 179 days after the index date. Documented SARS-CoV-2 infections were defined by SARS-CoV-
132 2 polymerase chain reaction, antigen or serology positive, or diagnosis of COVID-19, PASC or
133 multisystem inflammatory syndrome (MIS). The index date was set as either the earliest date of positive
134 tests or COVID-19 diagnoses or 28 days before PASC/MIS diagnosis.

135 Participants were excluded if they aged below 5 at the time of assessing BMI due to their potential for
136 more dramatic BMI variations during the baseline period, and if they had genetic syndromes associated
137 with obesity or any conditions signaling a need for weight gain or a medical cause of altered weight
138 tendencies during the baseline period (eTable 2 in the Supplement). The participants selection process is
139 summarized in eFigure 1 in the Supplement.

140 **Defining BMI Status**

141 When multiple BMI (weight (kg)/height (m)²) measures were available during the baseline period, we
142 selected the measure closest to the index date. For participants aged 5-19 years, according to the age-sex-
143 specific BMI percentiles based on CDC Growth Charts, the BMI status was categorized into healthy
144 weight (5th to less than 85th percentile), overweight (85th to less than 95th percentile), obesity (95th
145 percentile to less than 120% of the 95th percentile), and severe obesity (120% of the 95th percentile or
146 greater);²¹ for participants aged above 19 years, these four categories were divided by BMI of 18.5 to less
147 than 25, 25 to less than 30, 30 to less than 40, and 40 or more within the baseline period.²²

148 **Defining PASC**

149 The outcome was assessed within the follow-up period. We first used ICD-10-CM codes, U09.9, specific
150 for post-COVID-19 condition to indicate PASC. For this, we created a binary outcome, PASC (U09.9),
151 which was defined as positive if anyone who was identified as having PASC with a U09.9 diagnosis code.
152 Second, we used clusters of symptoms and health conditions previously shown to constitute the PASC
153 phenotype based on experts' suggestions,^{23,24} including abdominal pain, abnormal liver enzyme, acute
154 kidney injury, acute respiratory distress syndrome, arrhythmias, cardiovascular signs and symptoms,
155 changes in taste and smell, chest pain, cognitive dysfunction, fatigue and malaise, fever and chills, fluid
156 and electrolyte imbalances, generalized pain, hair loss, headache, heart disease, mental health disorders,
157 musculoskeletal pain, myocarditis, myositis, postural orthostatic tachycardia syndrome or dysautonomia,
158 respiratory signs and symptoms, skin symptoms, thrombophlebitis and thromboembolism. We assessed
159 the incident occurrences of these 24 PASC symptoms and conditions within the follow-up period, but that
160 did not occur during the baseline period, and then a binary and a count outcome were created. The binary
161 outcome is defined as positive if any of these conditions occurred, and the count outcome is defined as the
162 total incident occurrences of these conditions.

163 **Covariates**

164 Age at BMI status assessment and age at cohort entry were collected. Other demographic characteristics
165 included sex (male/female), and race and ethnicity (Asian American/Pacific Islander, Hispanic, Non-
166 Hispanic Black, and Non-Hispanic White). The predominating COVID-19 virus variant was categorized
167 as pre-Alpha (2020-03-01~2021-03-31), Alpha (2021-04-01~2021-06-30), Delta (2021-07-01~2021-12-
168 31), and Omicron (2022-01-01~2022-12-01).²⁵ We used numbers of emergency department/ outpatient
169 department/inpatient department visits, medications or prescriptions, and negative COVID-19 tests up to
170 24 months before index date as healthcare utilization metrics, and the Pediatric Medical Complexity
171 Algorithm (PMCA)²⁶ index to address levels of medical complexity comorbidity (no/non-
172 complex/complex chronic condition) for the pediatrics. We also classified participants based on the acute
173 COVID-19 severity as asymptomatic, mild, moderate, and severe.²⁷ Doses of COVID-19 vaccine prior to
174 infection and interval since last COVID-19 vaccination date (no vaccine/<4 months/≥4 months), and type
175 of insurance (private/public/others) were also considered in the secondary analyses.

176 **Statistical Analysis**

177 We first presented the demographic and clinical characteristics across different BMI statuses.
178 Comparisons of PASC (U09.9) and potential PASC symptoms and conditions were then made by BMI
179 status. For the count outcome, total incident occurrences of PASC symptoms and conditions, we used
180 Poisson regression to assess its association with BMI status by estimating the relative risk (RR) and 95%
181 confidence interval (CI), adjusting for demographic characteristics (age, sex, race/ethnicity), predominant
182 variant, healthcare utilization metrics prior to cohort entry, PMCA index, and acute COVID-19. For
183 binary outcomes, PASC (U09.9) and any incident occurrences of PASC symptoms and conditions,
184 modified Poisson regression²⁸ was employed, accounting for possible variance overestimation and
185 adjusting for the factors described above. Analysis of variance was used for the linear trend test.
186 Subgroup analyses were performed by age (<18 or ≥18 years) and PMCA index (no chronic condition or

187 non-complex/complex chronic condition), and by race/ethnicity as disparities exist in the BMI status
188 among children and the severity of COVID-19 by race/ethnicity to test for potential effect modification.

189 We performed sensitivity analyses to validate our findings. First, we excluded participants whose BMI
190 status assessment date was beyond 6 months before cohort entry as pediatric BMI tended to increase
191 during the pandemic.²⁹ Second, participants whose entrance date was before the time U09.9 was released
192 (i.e., October 1, 2021) were excluded considering possible low usage of U09.9 by clinicians when the
193 code was first introduced. We then excluded patient confirmed by serology test after November 2022 due
194 to the test's possible accuracy issues. Fourth, to investigate whether the observed associations were
195 explained by the acute COVID-19 severity, we excluded participants with moderate or severe infection.

196 Fifth, as vaccination against COVID-19 may reduce PASC risk,^{30,31} we additionally adjusted for
197 vaccination status before infection. Sixth, insurance type was further adjusted to examine whether
198 socioeconomic factors might account for the association. Seventh, participants with diabetes were
199 excluded as diabetes has been reported as a risk factor for PASC.^{32,33} Eighth, we excluded obese
200 participants without diabetes using weight-loss drugs during the baseline period to investigate whether
201 weight-loss drugs impact the association. Ninth, we conducted an analysis based on primary care sites to
202 ascertain the generalizability of our findings within a community-based primary care setting. We also
203 used foreign body in ear as a negative control outcome to account for the impacts due to residual bias.^{34,35}

204 All analyses were conducted using R version 4.1.2 (The R Foundation).

205 **Results**

206 After excluding participants who were underweight (n=221) and missed BMI status (n=67451), a total of
207 172136 participants were included in the analysis. Participants missing BMI status data were more prone
208 to be younger, male, Non-Hispanic White and Non-Hispanic Black, be infected after the pre-Alpha wave,
209 have lower complex chronic conditions, use healthcare utilization less, and be less likely to develop
210 PASC (eTable 3 in the Supplement). The median time from BMI status assessment to COVID-19

211 infection was 4.1 months (IQR 1.6-8.6). Of all the participants, 90187 (52.4%) were female, 87275
212 (50.7%) were Non-Hispanic White, and 85613 (49.7%) had obesity or severe obesity (Table 1).
213 During the follow-up period, 1402 (0.8%) participants were diagnosed as PASC (U09.9), of which 751
214 (53.6%) were obese or severely obese; and 74317 (43.2%) participants had at least one incident
215 occurrences of PASC symptoms and conditions, of which 38006 (51.1%) were obese or severely obese.
216 The median of the total number of incident occurrences of PASC symptoms and conditions was 0,
217 signifying that at least half of the participants in the cohort did not experience any incident occurrences of
218 PASC symptoms and conditions.

219 Participants classified as having overweight, obesity, or severe obesity exhibited an increased risk of
220 PASC compared to those with healthy weight, albeit not all reaching statistical significance. Specifically,
221 in comparison to those with healthy weight, participants categorized as having obesity and severe obesity
222 demonstrated a noteworthy 25.4% (RR, 1.254; 95% CI, 1.064-1.478) and 42.1% (RR, 1.421; 95% CI,
223 1.253-1.611) higher risk of PASC (U09.9), respectively. Similarly, those who had obesity and severe
224 obesity experienced a 10.8% (RR, 1.108; 95% CI, 1.064-1.154) and 17.4% (RR, 1.174; 95% CI, 1.138-
225 1.213) increased likelihood of encountering any manifestation of potential PASC symptoms and
226 conditions, respectively. Furthermore, when assessing the cumulative occurrences of PASC symptoms
227 and conditions, the association became slightly more pronounced and the RRs for those who had
228 overweight, obesity, and severe obesity were 1.053 (95% CI, 1.000-1.109), 1.137 (95% CI, 1.088-1.188),
229 and 1.182 (95% CI, 1.142-1.223), respectively. A significant dose-response relationship emerged between
230 worsening BMI classification and risk of PASC ($P < 0.05$ from the linear trend test) (Table 2).

231 Similar association was identified in the subgroup analysis by age and PMAC index, and the result did
232 not differ significantly in the analysis for Non-Hispanic White, yet the association was not observed in the
233 PASC (U09.9) for Non-Hispanic Black, neither was in all the PASC outcomes for Hispanic (Table 3),
234 where the analysis for American/Pacific Islander was not present because the case of U09.9 diagnosis in

235 certain BMI status categories was too small. The significant dose-response relationship still held in the
236 sensitivity analysis although slightly changes were seen in the associations (eTables 4-14 in the
237 Supplement). The result for negative control outcome analysis was insignificant, indicating that residual
238 bias was not observed (eTable 15 in the Supplement).

239 **Discussion**

240 To our knowledge, this retrospective cohort study is the first and the largest to explore the relationship
241 between BMI status and PASC among the pediatric population. Within the follow-up period, an adverse
242 dose-response relationship between pre-infection BMI status and the susceptibility to PASC was
243 consistently revealed, after adjusting for sociodemographic and clinical variables. This association pattern
244 between BMI status and PASC risk was consistent across pediatric and adult populations¹⁹, albeit with
245 varying magnitudes of association. This association persisted even after rigorous adjustments for critical
246 factors through secondary analyses, except for the subgroup analysis by racial and ethnic minorities,
247 suggesting that race/ethnicity may be an effect modifier. Importantly, the incorporation of negative
248 control outcome yielded no sizable residual bias, confirming the robustness and reliability of the findings.

249 Our study had several strengths. A pivotal one lies in its extensive and representative sample. Covering
250 172136 pediatric populations with COVID-19 infection from twenty-six US children's hospitals, our
251 study is distinguished by its scale, enabling us ample statistical power to rigorously evaluate the BMI-
252 PASC relationship accounting for key sociodemographic and clinical risk factors. A noteworthy
253 distinction from the previous research is our ICD-coded EHR phenotypes rather than self-reported PASC
254 symptoms as the latter may be influenced by individual perceptions, interpretations, recall biases, lack of
255 standardization, participant compliance with reporting protocols, etc. The inclusion of multiple PASC
256 outcomes enhances the clarity in understanding the burden and risk of PASC, and mitigates the potential
257 for misclassification. This is particularly relevant given the recognized limitations associated with only
258 using U09.9³⁶ and acknowledging the likely divergence in clinical features of PASC between pediatric

259 and adult population.²³ Moreover, a considerable portion of the existing studies primarily focused solely
260 on hospitalized cohorts, our cohort is characterized by its inclusivity, incorporating both non-hospitalized
261 and hospitalized participants.

262 Although our study revealed a significantly higher obesity rate (35.7% vs. 49.7% before and after
263 excluding those who were underweight and missed BMI status) compared to the national average
264 (19.7%),¹⁵ the rate among participants from primary care sites was comparable (17.52% vs. 22.36%
265 before and after excluding those who were underweight and missed BMI status). This disparity may be
266 attributed to better overall health among participants from primary care sites, as well as the heightened
267 susceptibility to various health conditions among overweight or obese individuals.³⁷ Higher BMI has also
268 been associated with increased risks of hospitalization³⁸ and severe illness³⁹ among pediatric COVID-19
269 patients. Alternatively, it is possible that pediatric BMI levels, particularly in the overweight²⁹ and
270 obesity⁴⁰ categories, increased during the pandemic, which could explain the increased RRs observed for
271 individual in these categories in the sensitivity analysis, which excluded participants whose BMI
272 assessment date was beyond 6 months before cohort entry. The BMI-PASC association remained
273 consistent across the outcome measures, although stronger associations were observed for U09.9. The
274 differences observed could stem from the specificity of PASC symptoms and conditions compared to
275 U09.9. Recognizing the limitations associated with the use of U09.9³⁶ and PASC symptoms and
276 conditions,²³ we incorporated both measures to enhance the comprehensiveness and precision in our
277 analysis.

278 The associations observed in our study may be explained by several plausible biological mechanisms,
279 although they may not be pediatric-specific. Firstly, obesity's association with chronic inflammation^{41,42}
280 and susceptibility to COVID-19 may involve macrophages pyroptosis,⁴³ leading to prolonged systemic
281 inflammation implicated in the genesis of PASC.^{44,45} Secondly, obesity is also associated with altered
282 microbiota,⁴⁶ and the impact of COVID-19 on the latter may influence PASC risk.⁴⁷ Thirdly, obesity is
283 recognized for its propensity to dysregulate adaptive autoimmunity,^{48,49} a phenomenon documented in

284 PASC patients.^{50,51} This dysregulation in adaptive immune responses may be implicated in the protracted
285 nature of observed symptoms. Furthermore, clotting and endothelial abnormalities associated with obesity
286 could explain observed pathophysiological changes in PASC patients.^{50,52-54}

287 Our study has several limitations. Firstly, the high prevalence of obesity among participants may indicate
288 sample skewness, which can be explained by several factors, including the missing BMI status data
289 within the baseline period, as discussed above, thus necessitating cautious generalization to the entire US
290 pediatric population. Additionally, misclassification bias challenges pediatric PASC diagnosis due to the
291 lack of standardized reference. To mitigate this, we used ICD-10-CM codes and PASC symptoms and
292 conditions, though the latter may not capture all aspects. Moreover, some PASC symptoms and
293 conditions we examined may overlap with those in pediatric populations with obesity, potentially
294 inflating the association. However, we assessed the incidence of these symptoms and conditions do not
295 present during the baseline period, which may alleviate this issue. To address the probable
296 underestimation of the PASC burden, we included participants with at least one visit two years before
297 cohort entry and one during the follow-up period. Furthermore, the absence of information on modifiable
298 risk factors, such as diet, physical activity, or sleep in our dataset is notable. Previous study has linked
299 these factors to a substantially reduced PASC risk.¹⁹ Therefore, further investigations including these
300 modifiable factors involving the pediatric population are warranted.

301 **Conclusion**

302 Our study reveals a significant association between higher pre-SARS-CoV-2 infection BMI and increased
303 PASC risk in pediatric patients, which contributes to the understanding and management of PASC in this
304 context. Given the potential for associated PASC conditions to become lifelong chronic conditions,
305 understanding pediatric PASC is important. Clinically, this association emphasizes the need for vigilant
306 monitoring and tailored management for this demographic with elevated BMI who have had COVID-19.
307 Pediatricians play a vital role in identifying at-risk individuals and implementing personalized treatment
308 plans to mitigate long-term consequences. From a public health standpoint, recognizing the connection

309 between elevated BMI and PASC highlights the importance of preventive interventions. Public health
310 initiatives can raise awareness about the heightened PASC risk among obese pediatrics, promoting
311 healthy lifestyle behaviors to reduce severe COVID-19 outcomes. Collaborative efforts are essential for
312 implementing programs that promote healthy weight management and foster supportive environments.
313 Addressing obesity as a modifiable risk factor for pediatric PASC can alleviate the burden of PASC and
314 further the broader goals of pediatric health post-pandemic. Further research should explore specific
315 PASC symptoms and conditions across various organ systems.

316 **Disclosures**

317 **Disclaimer**

318 This content is solely the responsibility of the authors and does not necessarily represent the official views
319 of the RECOVER Initiative, the NIH, or other funders.

320 **Funding**

321 This work was supported in part by the National Institutes of Health (OT2HL161847-01,
322 1R01LM012607, 1R01AI130460, 1R01AG073435, 1R56AG074604, 1R01LM013519, 1R56AG069880,
323 1R01AG077820, 1U01TR003709). This work was supported partially through the Patient-Centered
324 Outcomes Research Institute (PCORI) Project Program Awards (ME-2019C3-18315 and ME-2018C3-
325 14899). All statements in this report, including its findings and conclusions, are solely those of the
326 authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute
327 (PCORI), its Board of Governors, or the Methodology Committee.

328 **Potential Conflicts of Interest**

329 Dr. Rao received research support from GSK and Biofire and was a consultant for Sequiris. Dr. Chu is an
330 employee of Pfizer. All other authors have indicated they have no conflicts of interest relevant to this
331 manuscript to disclose.

332 **Acknowledgements**

333 This study is part of the NIH Researching COVID-19 to Enhance Recovery (RECOVER) Initiative,
334 which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection (PASC).
335 For more information on RECOVER, visit <https://recovercovid.org/>.

336 We would like to thank the National Community Engagement Group (NCEG), all patients, caregivers,
337 and community Representatives, and all the participants enrolled in the RECOVER Initiative. We want to
338 thank to Max Hornig, Teresa Akintonwa, Etienne Carignan for their helpful suggestions on our
339 manuscript.

340 **REFERENCES**

- 341 1. Venkatesan P. NICE guideline on long COVID. *Lancet Respir Med*. 2021;9(2):129.
342 doi:10.1016/S2213-2600(21)00031-X
- 343 2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J V. A clinical case definition of
344 post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*.
345 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9
- 346 3. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum
347 of Disease Due to SARS-CoV-2 Infection. *JAMA*. 2020;324(22):2251.
348 doi:10.1001/jama.2020.22717
- 349 4. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-
350 acute covid-19 in primary care. *BMJ*. Published online August 11, 2020:m3026.
351 doi:10.1136/bmj.m3026
- 352 5. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute
353 sequelae of COVID-19. *Nature*. 2021;594(7862):259-264. doi:10.1038/s41586-
354 021-03553-9
- 355 6. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat*
356 *Med*. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
- 357 7. Montani D, Savale L, Noel N, et al. Post-acute COVID-19 syndrome. *European*
358 *Respiratory Review*. 2022;31(163):210185. doi:10.1183/16000617.0185-2021
- 359 8. Davis HE, McCorkell L, Vogel JM, Topol EJ. Author Correction: Long COVID:
360 major findings, mechanisms and recommendations. *Nat Rev Microbiol*.
361 2023;21(6):408. doi:10.1038/s41579-023-00896-0
- 362 9. Morello R, Mariani F, Mastrantoni L, et al. Risk factors for post-COVID-19
363 condition (Long Covid) in children: a prospective cohort study. *EClinicalMedicine*.
364 2023;59:101961. doi:10.1016/j.eclinm.2023.101961
- 365 10. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, et al. Long-COVID in
366 children and adolescents: a systematic review and meta-analyses. *Sci Rep*.
367 2022;12(1):9950. doi:10.1038/s41598-022-13495-5
- 368 11. Jiang L, Li X, Nie J, Tang K, Bhutta ZA. A Systematic Review of Persistent
369 Clinical Features After SARS-CoV-2 in the Pediatric Population. *Pediatrics*.
370 2023;152(2). doi:10.1542/peds.2022-060351
- 371 12. Zheng YB, Zeng N, Yuan K, et al. Prevalence and risk factor for long COVID in
372 children and adolescents: A meta-analysis and systematic review. *J Infect Public*
373 *Health*. 2023;16(5):660-672. doi:10.1016/j.jiph.2023.03.005
- 374 13. *COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19*.
375 National Institute for Health and Care Excellence (NICE); 2020.
- 376 14. <https://www.cdc.gov/obesity/data/adult.html>.
- 377 15. Childhood Obesity Facts. Accessed November 29, 2023.
378 <https://www.cdc.gov/obesity/data/childhood.html>
- 379 16. Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for
380 COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive
381 Mechanical Ventilation, and Death — United States, March–December 2020.
382 *MMWR Morb Mortal Wkly Rep*. 2021;70(10):355-361.
383 doi:10.15585/mmwr.mm7010e4

- 384 17. Thompson EJ, Williams DM, Walker AJ, et al. Long COVID burden and risk
385 factors in 10 UK longitudinal studies and electronic health records. *Nat Commun.*
386 2022;13(1):3528. doi:10.1038/s41467-022-30836-0
- 387 18. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors
388 for long COVID in non-hospitalized adults. *Nat Med.* 2022;28(8):1706-1714.
389 doi:10.1038/s41591-022-01909-w
- 390 19. Wang S, Li Y, Yue Y, et al. Adherence to Healthy Lifestyle Prior to Infection and
391 Risk of Post-COVID-19 Condition. *JAMA Intern Med.* 2023;183(3):232.
392 doi:10.1001/jamainternmed.2022.6555
- 393 20. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID.
394 *Nat Med.* 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- 395 21. BMI and BMI Categories for Children and Teens. Accessed November 14, 2023.
396 <https://www.cdc.gov/obesity/basics/childhood-defining.html>
- 397 22. Defining Adult Overweight & Obesity. Accessed November 14, 2023.
398 <https://www.cdc.gov/obesity/basics/adult-defining.html>
- 399 23. Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute
400 Sequelae of SARS-CoV-2 Infection in Children and Adolescents. *JAMA Pediatr.*
401 2022;176(10):1000. doi:10.1001/jamapediatrics.2022.2800
- 402 24. Razzaghi H, Forrest CB, Hirabayashi K, et al. Vaccine Effectiveness Against Long
403 COVID in Children. *Pediatrics.* 2024;153(4). doi:10.1542/peds.2023-064446
- 404 25. [https://ourworldindata.org/grapher/covid-variants-area?time=2021-06-21..2021-12-](https://ourworldindata.org/grapher/covid-variants-area?time=2021-06-21..2021-12-20&facet=none&country=~USA)
405 [20&facet=none&country=~USA.](https://ourworldindata.org/grapher/covid-variants-area?time=2021-06-21..2021-12-20&facet=none&country=~USA)
- 406 26. Simon TD, Cawthon ML, Stanford S, et al. Pediatric medical complexity algorithm:
407 a new method to stratify children by medical complexity. *Pediatrics.*
408 2014;133(6):e1647-54. doi:10.1542/peds.2013-3875
- 409 27. Forrest CB, Burrows EK, Mejias A, et al. Severity of Acute COVID-19 in Children
410 <18 Years Old March 2020 to December 2021. *Pediatrics.* 2022;149(4).
411 doi:10.1542/peds.2021-055765
- 412 28. Zou G. A Modified Poisson Regression Approach to Prospective Studies with
413 Binary Data. *Am J Epidemiol.* 2004;159(7):702-706. doi:10.1093/aje/kwh090
- 414 29. Knapp EA, Dong Y, Dunlop AL, et al. Changes in BMI During the COVID-19
415 Pandemic. *Pediatrics.* 2022;150(3). doi:10.1542/peds.2022-056552
- 416 30. Ayoubkhani D, Birmingham C, Pouwels KB, et al. Trajectory of long covid
417 symptoms after covid-19 vaccination: community based cohort study. *BMJ.*
418 Published online May 18, 2022:e069676. doi:10.1136/bmj-2021-069676
- 419 31. Ceban F, Kulzhabayeva D, Rodrigues NB, et al. COVID-19 vaccination for the
420 prevention and treatment of long COVID: A systematic review and meta-analysis.
421 *Brain Behav Immun.* 2023;111:211-229. doi:10.1016/j.bbi.2023.03.022
- 422 32. Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk Factors Associated With
423 Post-COVID-19 Condition. *JAMA Intern Med.* 2023;183(6):566.
424 doi:10.1001/jamainternmed.2023.0750
- 425 33. Pfaff ER, Girvin AT, Bennett TD, et al. Identifying who has long COVID in the
426 USA: a machine learning approach using N3C data. *Lancet Digit Health.*
427 2022;4(7):e532-e541. doi:10.1016/S2589-7500(22)00048-6
- 428 34. Schuemie MJ, Hripesak G, Ryan PB, Madigan D, Suchard MA. Empirical
429 confidence interval calibration for population-level effect estimation studies in

- 430 observational healthcare data. *Proceedings of the National Academy of Sciences*.
431 2018;115(11):2571-2577.
- 432 35. Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting
433 observational studies: why empirical calibration is needed to correct p-values. *Stat*
434 *Med*. 2014;33(2):209-218.
- 435 36. Pfaff ER, Madlock-Brown C, Baratta JM, et al. Coding Long COVID:
436 Characterizing a new disease through an ICD-10 lens. *medRxiv*. Published online
437 September 2, 2022. doi:10.1101/2022.04.18.22273968
- 438 37. <https://www.cdc.gov/healthyweight/effects/index.html>.
- 439 38. Mohammad S, Aziz R, Al Mahri S, et al. Obesity and COVID-19: what makes
440 obese host so vulnerable? *Immunity & Ageing*. 2021;18(1):1. doi:10.1186/s12979-
441 020-00212-x
- 442 39. Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk
443 factors for COVID-19-associated hospitalisations and death: systematic review and
444 meta-analysis. *BMJ Nutr Prev Health*. 2022;5(1):10-18. doi:10.1136/bmjnp-2021-
445 000375
- 446 40. Lartey ST, Jayawardene WP, Dickinson SL, Chen X, Gletsu-Miller N, Lohrmann
447 DK. Evaluation of Unintended Consequences of COVID-19 Pandemic Restrictions
448 and Obesity Prevalence Among Youths. *JAMA Netw Open*. 2023;6(7):e2323596.
449 doi:10.1001/jamanetworkopen.2023.23596
- 450 41. Korakas E, Ikonomidis I, Kousathana F, et al. Obesity and COVID-19: immune and
451 metabolic derangement as a possible link to adverse clinical outcomes. *American*
452 *Journal of Physiology-Endocrinology and Metabolism*. 2020;319(1):E105-E109.
453 doi:10.1152/ajpendo.00198.2020
- 454 42. Hildebrandt X, Ibrahim M, Peltzer N. Cell death and inflammation during obesity:
455 “Know my methods, WAT(son).” *Cell Death Differ*. 2023;30(2):279-292.
456 doi:10.1038/s41418-022-01062-4
- 457 43. López-Reyes A, Martínez-Armenta C, Espinosa-Velázquez R, et al. NLRP3
458 Inflammasome: The Stormy Link Between Obesity and COVID-19. *Front*
459 *Immunol*. 2020;11. doi:10.3389/fimmu.2020.570251
- 460 44. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk
461 factors, and management. *BMJ*. Published online July 26, 2021:n1648.
462 doi:10.1136/bmj.n1648
- 463 45. Woodruff MC, Bonham KS, Anam FA, et al. Chronic inflammation, neutrophil
464 activity, and autoreactivity splits long COVID. *Nat Commun*. 2023;14(1):4201.
465 doi:10.1038/s41467-023-40012-7
- 466 46. Zsálíg D, Berta A, Tóth V, et al. A Review of the Relationship between Gut
467 Microbiome and Obesity. *Applied Sciences*. 2023;13(1):610.
468 doi:10.3390/app13010610
- 469 47. Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of
470 patients with post-acute COVID-19 syndrome. *Gut*. 2022;71(3):544-552.
471 doi:10.1136/gutjnl-2021-325989
- 472 48. Kwiat VR, Reis G, Valera IC, Parvatiyar K, Parvatiyar MS. Autoimmunity as a
473 sequela to obesity and systemic inflammation. *Front Physiol*. 2022;13.
474 doi:10.3389/fphys.2022.887702

- 475 49. Tsigalou C, Vallianou N, Dalamaga M. Autoantibody Production in Obesity: Is
476 There Evidence for a Link Between Obesity and Autoimmunity? *Curr Obes Rep.*
477 2020;9(3):245-254. doi:10.1007/s13679-020-00397-8
- 478 50. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19
479 (PASC): An Overview of Biological Factors That May Contribute to Persistent
480 Symptoms. *Front Microbiol.* 2021;12. doi:10.3389/fmicb.2021.698169
- 481 51. Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-
482 19 sequelae. *Cell.* 2022;185(5):881-895.e20. doi:10.1016/j.cell.2022.01.014
- 483 52. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. *Curr Opin Hematol.*
484 2013;20(5):437-444. doi:10.1097/MOH.0b013e3283634443
- 485 53. Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial Dysfunction in Obesity-
486 Induced Inflammation: Molecular Mechanisms and Clinical Implications.
487 *Biomolecules.* 2020;10(2):291. doi:10.3390/biom10020291
- 488 54. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein
489 thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-
490 controlled cases series and matched cohort study. *BMJ.* Published online April 6,
491 2022:e069590. doi:10.1136/bmj-2021-069590
- 492
- 493

494 **Table 1. Characteristics by BMI status prior to the SARS-CoV-2 infection pediatric participants ^a**

Characteristics	Healthy weight (N=68918)	Overweight (N=17605)	Obesity (N=25372)	Severe obesity (N=60241)	Overall (N=172136)
Age, mean (SD), yr					
Assessed BMI	12.6 (4.5)	12.8 (4.3)	11.3 (4.2)	13.1 (4.2)	12.6 (4.4)
Entered cohort	13.0 (4.5)	13.2 (4.3)	11.8 (4.2)	13.6 (4.2)	13.1 (4.4)
Sex, no. (%)					
Female	36011 (52.3)	9580 (54.4)	11627 (45.8)	32969 (54.7)	90187 (52.4)
Male	32907 (47.7)	8025 (45.6)	13745 (54.2)	27272 (45.3)	81949 (47.6)
Race/ethnicity, no. (%)					
AAPI	3996 (5.8)	770 (4.4)	1055 (4.2)	2993 (5.0)	8814 (5.1)
Hispanic	10657 (15.5)	3588 (20.4)	7335 (28.9)	21402 (35.5)	42982 (25.0)
NHB	11980 (17.4)	3854 (21.9)	6004 (23.7)	11227 (18.6)	33065 (19.2)
NHW	42285 (61.4)	9393 (53.4)	10978 (43.3)	24619 (40.9)	87275 (50.7)
Predominant variant, no. (%)					
Pre-Alpha	18204 (26.4)	4592 (26.1)	5920 (23.3)	16724 (27.8)	45440 (26.4)
Alpha	3641 (5.3)	968 (5.5)	1354 (5.3)	2592 (4.3)	8555 (5.0)
Delta	17001 (24.7)	4688 (26.6)	7063 (27.8)	13738 (22.8)	42490 (24.7)
Omicron	30072 (43.6)	7357 (41.8)	11035 (43.5)	27187 (45.1)	75651 (43.9)
PMCA, no. (%)					
None	41656 (60.4)	10071 (57.2)	14427 (56.9)	39140 (65.0)	105294 (61.2)
Noncomplex	15755 (22.9)	4470 (25.4)	6521 (25.7)	13389 (22.2)	40135 (23.3)
Complex	11507 (16.7)	3064 (17.4)	4424 (17.4)	7712 (12.8)	26707 (15.5)
Acute COVID-19 Severity, no. (%)					
Asymptomatic	43807 (63.6)	11277 (64.1)	15528 (61.2)	31754 (52.7)	102366 (59.5)
Mild	20867 (30.3)	5205 (29.6)	8309 (32.7)	26347 (43.7)	60728 (35.3)
Moderate	2617 (3.8)	725 (4.1)	978 (3.9)	1384 (2.3)	5704 (3.3)
Severe	1627 (2.4)	398 (2.3)	557 (2.2)	756 (1.3)	3338 (1.9)
Location diagnosed COVID-19, no. (%)					
ED	7830 (11.4)	2562 (14.6)	3511 (13.8)	3185 (5.3)	17088 (9.9)
IPD	2325 (3.4)	548 (3.1)	764 (3.0)	934 (1.6)	4771 (2.7)
OPD	28645 (41.6)	6898 (39.2)	12126 (47.8)	41270 (68.5)	88939 (51.7)
OPD:Test Only	13700 (19.9)	3623 (20.6)	4814 (19.0)	9750 (16.2)	31887 (18.5)
Other/Unknown	16418 (23.8)	3974 (22.6)	4157 (16.4)	5102 (8.5)	29651 (17.2)
Numbers of negative COVID-19 tests, no. (%)					
0	39837 (57.8)	10073 (57.2)	14939 (58.9)	39463 (65.5)	104312 (60.6)
1	15426 (22.4)	3990 (22.7)	5671 (22.4)	11877 (19.7)	36964 (21.5)
≥2	13655 (19.8)	3542 (20.1)	4762 (18.8)	8901 (14.8)	30860 (17.9)
Numbers of ED visits, no. (%)					
0	49015 (71.1)	11729 (66.6)	17601 (69.4)	51517 (85.5)	129862 (75.4)
1	11041 (16.0)	3021 (17.2)	3868 (15.2)	4966 (8.2)	22896 (13.3)
2	4368 (6.3)	1270 (7.2)	1682 (6.6)	1798 (3.0)	9118 (5.3)
≥3	4494 (6.5)	1585 (9.0)	2221 (8.8)	1960 (3.3)	10260 (6.0)
Numbers of IPD visits, no. (%)					
0	62276 (90.4)	15831 (89.9)	23123 (91.1)	57596 (95.6)	158826 (92.3)
1	4101 (6.0)	1132 (6.4)	1462 (5.8)	1709 (2.8)	8404 (4.9)
2	1191 (1.7)	306 (1.7)	400 (1.6)	486 (0.8)	2383 (1.4)
≥3	1350 (2.0)	336 (1.9)	387 (1.5)	450 (0.7)	2523 (1.5)
Numbers of OPD visits, no. (%)					
0	2315 (3.4)	643 (3.7)	1374 (5.4)	4498 (7.5)	8830 (5.1)
1	6570 (9.5)	1751 (9.9)	2409 (9.5)	4544 (7.5)	15274 (8.9)
2	8355 (12.1)	2105 (12.0)	2866 (11.3)	5929 (9.8)	19255 (11.2)
≥3	51678 (75.0)	13106 (74.4)	18723 (73.8)	45270 (75.1)	128777 (74.8)
Numbers of medications or prescriptions, no. (%)					

0	9944 (14.4)	2235 (12.7)	3878 (15.3)	12364 (20.5)	28421 (16.5)
1	7759 (11.3)	1787 (10.2)	2627 (10.4)	7078 (11.7)	19251 (11.2)
2	6998 (10.2)	1639 (9.3)	2404 (9.5)	6591 (10.9)	17632 (10.2)
2+	44217 (64.2)	11944 (67.8)	16463 (64.9)	34208 (56.8)	106832 (62.1)
Dosage of vaccine, no. (%)					
0	53946 (78.3)	13975 (79.4)	20914 (82.4)	46248 (76.8)	135083 (78.5)
1	2519 (3.7)	620 (3.5)	901 (3.6)	2576 (4.3)	6616 (3.8)
2	9979 (14.5)	2477 (14.1)	3065 (12.1)	9308 (15.5)	24829 (14.4)
≥3	2474 (3.6)	533 (3.0)	492 (1.9)	2109 (3.5)	5608 (3.3)

495 Abbreviations: AAPI, Asian American/Pacific Islander; BMI, body mass index; ED, Emergency department; IPD, Inpatient department; NHB,
 496 Non-Hispanic Black; NHW, Non-Hispanic White; OPD, Outpatient department; PMCA, Pediatric Medical Complexity; SD, Standard deviation.
 497 ^a Percentages may not total 100 because of rounding.

498 **Table 2. Estimated association of BMI status prior to the SARS-CoV-2 infection and risk of PASC^a**

Outcome	BMI Status	Incident/total COVID (%) ^b	RR	LCI	UCI
PASC (U09.9)	Healthy weight	514/68918 (0.7)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	137/17605 (0.8)	1.047	0.868	1.263
	Obesity	199/25372 (0.8)	1.254	1.064	1.478
	Severe obesity	552/60241 (0.9)	1.421	1.253	1.611
	<i>P</i> for trend	NA		0.001	
PASC symptoms and conditions	Any Occurrences				
	Healthy weight	28674/68918 (41.6)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	7637/17605 (43.4)	1.030	0.982	1.080
	Obesity	11081/25372 (43.7)	1.108	1.064	1.154
	Severe obesity	26925/60241 (44.7)	1.174	1.138	1.213
	<i>P</i> for trend	NA		<0.001	
	Total Occurrences				
	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.053	1.000	1.109
	Obesity	NA	1.137	1.088	1.188
Severe obesity	NA	1.182	1.142	1.223	
<i>P</i> for trend	NA		<0.001		

499 Abbreviation: BMI, body mass index; LCI, lower 95% confidence interval; NA, not applicable; PASC, post-acute sequelae of SARS-CoV-2
500 infection; RR, relative risk; UCI, upper 95% confidence interval

501 ^a Adjusted for age assessed BMI and entered cohort (continuous), sex, race/ethnicity, PMCA index, predominant variant, acute COVID-19
502 severity, numbers of emergency department visits, outpatient department, inpatient department, medications or prescriptions, and negative
503 COVID-19 tests

504 ^b Incident referred to the count of participants developed the outcome we interested in, total COVID referred to the count of the participants in the
505 corresponding group, and the value in the bracket referred to the percentage of the groups who developed the outcome we interested in.

506 **Table 3. Estimated association of BMI status prior to the SARS-CoV-2 infection and risk of PASC**
 507 **in subgroups based on age, PMAC index, and race and ethnicity**

Outcome	BMI Status	Incident/total COVID (%) ^a	RR	LCI	UCI
Age, <18 yr (N=145975)^{b,c}					
PASC (U09.9)	Healthy weight	408/57916 (0.7)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	110/14994 (0.7)	1.052	0.854	1.298
	Obesity	173/23198 (0.7)	1.279	1.070	1.528
	Severe obesity	424/49867 (0.9)	1.429	1.238	1.648
	<i>P</i> for trend	NA		0.008	
Any Occurrences					
PASC symptoms and conditions	Healthy weight	23860/57916 (41.2)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	6409/14994 (42.7)	1.020	0.970	1.074
	Obesity	9991/23198 (43.1)	1.099	1.053	1.146
	Severe obesity	21923/49867 (44.0)	1.171	1.131	1.212
	<i>P</i> for trend	NA		<0.001	
Total Occurrences					
PASC symptoms and conditions	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.041	0.985	1.100
	Obesity	NA	1.121	1.070	1.173
	Severe obesity	NA	1.181	1.137	1.226
	<i>P</i> for trend	NA		<0.001	
Age, ≥18 yr (N=26161)^{b,c}					
PASC (U09.9)	Healthy weight	106/11002 (1.0)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	27/2611 (1.0)	1.014	0.663	1.552
	Obesity	26/2174 (1.2)	1.142	0.742	1.758
	Severe obesity	128/10374 (1.2)	1.367	1.047	1.784
	<i>P</i> for trend	NA		0.049	
Any Occurrences					
PASC symptoms and conditions	Healthy weight	4814/11002 (43.8)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	1228/2611 (47.0)	1.101	0.967	1.254
	Obesity	1090/2174 (50.1)	1.196	1.048	1.365
	Severe obesity	5002/10374 (48.2)	1.201	1.107	1.302
	<i>P</i> for trend	NA		<0.001	
Total Occurrences					
PASC symptoms and conditions	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.140	0.987	1.317
	Obesity	NA	1.304	1.124	1.512
	Severe obesity	NA	1.191	1.090	1.302
	<i>P</i> for trend	NA		0.002	
PMAC index, no chronic condition (N=105294)^d					
PASC (U09.9)	Healthy weight	316/41656 (0.8)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	73/10071 (0.7)	0.965	0.749	1.243
	Obesity	112/14427 (0.8)	1.260	1.015	1.565
	Severe obesity	353/39140 (0.9)	1.456	1.240	1.708
	<i>P</i> for trend	NA		0.023	
Any Occurrences					
PASC symptoms and conditions	Healthy weight	14914/41656 (35.8)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	3718/10071 (36.9)	0.999	0.944	1.058
	Obesity	5423/14427 (37.6)	1.116	1.064	1.170
	Severe obesity	15488/39140 (39.6)	1.184	1.141	1.228
	<i>P</i> for trend	NA		<0.001	
Total Occurrences					
PASC symptoms and conditions	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.021	0.960	1.085
	Obesity	NA	1.144	1.087	1.205

	Severe obesity	NA	1.195	1.149	1.243
	<i>P</i> for trend	NA		<0.001	
PMAC index, non-complex/complex chronic condition (N=66842)^d					
PASC (U09.9)	Healthy weight	198/27262 (0.7)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	64/7534 (0.8)	1.168	0.883	1.546
	Obesity	87/10945 (0.8)	1.255	0.975	1.615
	Severe obesity	199/21101 (0.9)	1.391	1.135	1.705
	<i>P</i> for trend	NA		0.013	
PASC symptoms and conditions	Any Occurrences				
	Healthy weight	13760/27262 (50.5)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	3919/7534 (52.0)	1.107	1.016	1.207
	Obesity	5658/10945 (51.7)	1.091	1.011	1.178
	Severe obesity	11437/21101 (54.2)	1.159	1.086	1.236
	<i>P</i> for trend	NA		<0.001	
	Total Occurrences				
	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.132	1.029	1.246
	Obesity	NA	1.121	1.031	1.218
Severe obesity	NA	1.156	1.077	1.240	
<i>P</i> for trend	NA		<0.001		
Race/ethnicity, Non-Hispanic White (N=87275)^e					
PASC (U09.9)	Healthy weight	371/42285 (0.9)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	83/9393 (0.9)	0.960	0.758	1.216
	Obesity	120/10978 (1.1)	1.298	1.058	1.592
	Severe obesity	333/24619 (1.4)	1.548	1.332	1.799
	<i>P</i> for trend	NA		<0.001	
PASC symptoms and conditions	Any Occurrences				
	Healthy weight	17827/42285 (42.2)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	4208/9393 (44.8)	1.022	0.958	1.091
	Obesity	5090/10978 (46.4)	1.074	1.011	1.142
	Severe obesity	12363/24619 (50.2)	1.224	1.171	1.280
	<i>P</i> for trend	NA		<0.001	
	Total Occurrences				
	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.039	0.968	1.115
	Obesity	NA	1.105	1.034	1.182
Severe obesity	NA	1.229	1.172	1.290	
<i>P</i> for trend	NA		<0.001		
Race/ethnicity, Hispanic (N=42982)^e					
PASC (U09.9)	Healthy weight	70/10657 (0.7)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	27/3588 (0.8)	1.108	0.712	1.725
	Obesity	48/7335 (0.7)	1.138	0.786	1.648
	Severe obesity	129/21402 (0.6)	1.020	0.757	1.374
	<i>P</i> for trend	NA		0.446	
PASC symptoms and conditions	Any Occurrences				
	Healthy weight	4758/10657 (44.6)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	1634/3588 (45.5)	1.016	0.918	1.125
	Obesity	3184/7335 (43.4)	1.045	0.959	1.140
	Severe obesity	8591/21402 (40.1)	1.154	1.073	1.241
	<i>P</i> for trend	NA		0.684	
	Total Occurrences				
	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.021	0.914	1.139
	Obesity	NA	1.076	0.980	1.182
Severe obesity	NA	1.167	1.078	1.263	

	<i>P</i> for trend	NA		0.638	
Race/ethnicity, Non-Hispanic Black (N=33065) ^e					
PASC (U09.9)	Healthy weight	53/11980 (0.4)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	21/3854 (0.5)	1.210	0.729	2.008
	Obesity	23/6004 (0.4)	0.916	0.563	1.492
	Severe obesity	66/11227 (0.6)	1.326	0.908	1.937
	<i>P</i> for trend	NA		0.204	
Any Occurrences					
PASC symptoms and conditions	Healthy weight	4665/11980 (38.9)	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	1514/3854 (39.3)	1.016	0.918	1.125
	Obesity	2370/6004 (39.5)	1.045	0.959	1.140
	Severe obesity	4827/11227 (43.0)	1.154	1.073	1.241
	<i>P</i> for trend	NA		<0.001	
Total Occurrences					
PASC symptoms and conditions	Healthy weight	NA	1 [Reference]	1 [Reference]	1 [Reference]
	Overweight	NA	1.021	0.914	1.139
	Obesity	NA	1.076	0.980	1.182
	Severe obesity	NA	1.167	1.078	1.263
	<i>P</i> for trend	NA		0.002	

Abbreviation: BMI, body mass index; LCI, lower 95% confidence interval; NA, not applicable; PASC, post-acute sequelae of SARS-CoV-2 infection; RR, relative risk; UCI, upper 95% confidence interval

^a Incident referred to the count of participants developed the outcome we interested in, total COVID referred to the count of the participants in the corresponding group, and the value in the bracket referred to the percentage of the groups who developed the outcome we interested in.

^b Adjusted for age assessed BMI and entered cohort (continuous), sex, race/ethnicity, PMCA index, predominant variant, acute COVID-19 severity, numbers of emergency department visits, outpatient department, inpatient department, medications or prescriptions, and negative COVID-19 tests

^c Stratified by the cohort entry age.

^d Adjusted for age assessed BMI and entered cohort (continuous), sex, predominant variant, acute COVID-19 severity, numbers of emergency department visits, outpatient department, inpatient department, medications or prescriptions, and negative COVID-19 tests

^e Adjusted for age assessed BMI and entered cohort (continuous), sex, PMCA index, predominant variant, acute COVID-19 severity, numbers of emergency department visits, outpatient department, inpatient department, medications or prescriptions, and negative COVID-19 tests

508
509
510
511
512
513
514
515
516
517
518
519